April 25, 2013
- -- First Quarter Non-GAAP Diluted EPS Rose 41% and GAAP Diluted EPS Up 43% -- -- TECFIDERA™ (Dimethyl Fumarate) Approved and Launched in the US as a First-Line Oral Treatment for Relapsing Forms of Multiple Sclerosis; EU Approval Pending -- -- Gained Full Strategic, Commercial and Decision-Making Rights to TYSABRI® -- WESTON, Mass.--(BUSINESS WIRE)--Apr. 25, 2013-- Biogen Idec Inc. (NASDAQ: BIIB) today reported first quarter 2013...
April 10, 2013
- WESTON, Mass.--(BUSINESS WIRE)--Apr. 10, 2013-- Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report first quarter 2013 financial results on Thursday, April 25, 2013, before the financial markets open. Following the release of the financials, the Company will host a live webcast where Biogen Idec management will discuss the financial results, at 8:00 am ET. To access the live webcast, please go to the investor relations section of Biogen...
April 4, 2013
- -Data Demonstrated That DAC HYP Significantly Reduced Annualized Relapse Rate by up to 54 Percent at One Year- -Phase 3 Study Underway to Further Assess Once-Monthly DAC HYP for Multiple Sclerosis- WESTON, Mass.--(BUSINESS WIRE)--Apr. 4, 2013-- Today Biogen Idec (NASDAQ: BIIB) announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as an online article in The Lancet. SELECT was a...
April 2, 2013
- WESTON, Mass.--(BUSINESS WIRE)--Apr. 2, 2013-- Biogen Idec (NASDAQ: BIIB) today announced it has completed its purchase of Elan Corporation’s interest in TYSABRI® (natalizumab) and has gained full strategic, commercial and decision-making rights to TYSABRI. The transaction was originally announced on February 6, 2013. “Full ownership of TYSABRI is an important step for Biogen Idec that further solidifies our leadership in MS,” said George A....
March 27, 2013
- - Offers a Broad Spectrum of Patients with Relapsing Forms of MS an Effective and Convenient Treatment Option - - Reduces Relapses and Disability Progression - - Strengthens Biogen Idec’s Portfolio of Innovative Treatments for People Living with MS - WESTON, Mass.--(BUSINESS WIRE)--Mar. 27, 2013-- Today Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TECFIDERA™ (dimethyl fumarate),...
March 22, 2013
- -European Commission Decision Anticipated In Second Quarter of 2013- WESTON, Mass.--(BUSINESS WIRE)--Mar. 22, 2013-- Today Biogen Idec (NASDAQ: BIIB) announced that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) recommending a marketing authorization be granted for TECFIDERA™ (dimethyl fumarate) as a first-line oral treatment for adults with relapsing-remitting multiple sclerosis...
March 20, 2013
- – Primary and Secondary Endpoints Met After One Year, Including Reductions in Relapses and Disability Progression – – Additional Data Demonstrate Significant Effects in Decreasing Brain Lesions – WESTON, Mass.--(BUSINESS WIRE)--Mar. 20, 2013-- Today Biogen Idec (NASDAQ: BIIB) announced the positive, full first-year results from its two-year pivotal Phase 3 ADVANCE study of PLEGRIDY™ (peginterferon beta-1a), the company’s investigational...
March 19, 2013
- – Patent Offers Protection Until 2028 and Strengthens Growing Product Patent Portfolio – – European Patent Office Also Determines Patent Application Covering the Same Dosing Regimen Allowable – WESTON, Mass.--(BUSINESS WIRE)--Mar. 19, 2013-- Biogen Idec (NASDAQ: BIIB) today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,399,514, which offers additional protection for TECFIDERA™ (dimethyl fumarate...
March 18, 2013
- – Continued Research into Risk Stratification and PML Early Detection Provides Additional Insights for Physicians – WESTON, Mass.--(BUSINESS WIRE)--Mar. 18, 2013-- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status...
- – Continued Research into Risk Stratification and PML Early Detection Provides Additional Insights for Physicians – WESTON, Mass.--(BUSINESS WIRE)--Mar. 18, 2013-- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced results from several studies of TYSABRI® (natalizumab) that demonstrate its efficacy compared to other multiple sclerosis (MS) treatments, provide additional data supporting anti-JC virus (JCV) antibody status...